FierceBiotech1d
Arch-backed Tenvie unveils with $200M and a neuro pipeline with assets from Denali
Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
STAT1d
Denali Therapeutics spinout raises $200M as neuro company resets
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
BioSpace1d
Tenvie Debuts With Denali Assets, $200M for Neurological, Metabolic Diseases
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
FierceBiotech3h
Light Horse lassos Novartis partnership worth up to $1B, wrangles $62M series A
Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...
STAT1d
East Asians under-represented in biopharma leadership
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Why biotech startup Tenvie sees promise in drugs from founders' old company
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule Therapies
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...
Innovaccer raises $275 million from B Capital Group, Kaiser Permanente and others
The last round in 2021 valued the healthcare technology firm at $3.2 billion, more than doubling its valuation from $1.3 ...